This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fulton, A. M. Articles by Kundu, N. Search for Related Content PubMed PubMed Citation Articles by Fulton, A. M. Articles by Kundu, N. Related Collections Tumor Biology: Invasion and Metastasis Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Targeting Prostaglandin E EP Receptors to Inhibit Metastasis

Department of Pathology and Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland

Requests for reprints: Amy M. Fulton, Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201. Phone: 410-706-6479; Fax: 410-706-8414; E-mail: afulton{at}umaryland.edu.

It is well established that high cyclooxygenase-2 (COX-2) expression contributes to the aggressive behavior of breast and other malignancies. Due to concerns regarding the safety of long-term use of COX-2 inhibitors as well as a desire to seek more effective alternatives to prevent and treat metastatic disease, we tested the hypothesis that inhibition of downstream signaling by the COX-2 product prostaglandin E₂ (PGE₂) would be as effective as inhibiting global prostaglandin synthesis. PGE₂ acts through four G-protein–coupled receptors designated EP1-4. Here, we summarize data from many laboratories regarding the role of individual E-series of prostaglandin (EP) receptors on cancer behavior and we discuss our own recent findings that antagonists of the PGE receptor subtype 4, EP4, inhibit experimental metastasis in a murine model of hormone-resistant, metastatic breast cancer. These initial results indicate that selective targeting of individual EP receptors should be investigated as an approach to exploit the high COX-2 activity in many epithelial malignancies. (Cancer Res 2006; 66(20): 9794-7)

This article has been cited by other articles:

				J. You, D. Mi, X. Zhou, L. Qiao, H. Zhang, X. Zhang, and L. Ye A Positive Feedback between Activated Extracellularly Regulated Kinase and Cyclooxygenase/Lipoxygenase Maintains Proliferation and Migration of Breast Cancer Cells Endocrinology, April 1, 2009; 150(4): 1607 - 1617. [Abstract] [Full Text] [PDF]

				A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis, March 1, 2009; 30(3): 377 - 386. [Abstract] [Full Text] [PDF]

				Y. Zheng, J. D. Ritzenthaler, X. Sun, J. Roman, and S. Han Prostaglandin E2 Stimulates Human Lung Carcinoma Cell Growth through Induction of Integrin-Linked Kinase: The Involvement of EP4 and Sp1 Cancer Res., February 1, 2009; 69(3): 896 - 904. [Abstract] [Full Text] [PDF]

				J.-M. Oh, S.-H. Kim, Y.-I. Lee, M. Seo, S.-Y. Kim, Y.-S. Song, W.-H. Kim, and Y.-S. Juhnn Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells Carcinogenesis, January 1, 2009; 30(1): 141 - 149. [Abstract] [Full Text] [PDF]

				J. R. Neil, K. M. Johnson, R. A. Nemenoff, and W. P. Schiemann Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-{beta} through a PGE2-dependent mechanisms Carcinogenesis, November 1, 2008; 29(11): 2227 - 2235. [Abstract] [Full Text] [PDF]

				L. Yu, W. K. K. Wu, Z. J. Li, H. P. S. Wong, E. K. K. Tai, H. T. Li, Y. C. Wu, and C. H. Cho E Series of Prostaglandin Receptor 2-Mediated Activation of Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Is Required for the Mitogenic Action of Prostaglandin E2 in Esophageal Squamous-Cell Carcinoma J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 258 - 267. [Abstract] [Full Text] [PDF]

				M. G. Backlund, J. M. Amann, and D. H. Johnson Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids J. Clin. Oncol., February 20, 2008; 26(6): 825 - 827. [Full Text] [PDF]

				D. Torres, C. Paget, J. Fontaine, T. Mallevaey, T. Matsuoka, T. Maruyama, S. Narumiya, M. Capron, P. Gosset, C. Faveeuw, et al. Prostaglandin D2 Inhibits the Production of IFN-{gamma} by Invariant NK T Cells: Consequences in the Control of B16 Melanoma J. Immunol., January 15, 2008; 180(2): 783 - 792. [Abstract] [Full Text] [PDF]

				N. Baryawno, B. Sveinbjornsson, S. Eksborg, A. Orrego, L. Segerstrom, C. O. Oqvist, S. Holm, B. Gustavsson, B. Kagedal, P. Kogner, et al. Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets Neuro-oncol, January 1, 2008; 10(5): 661 - 674. [Abstract] [Full Text] [PDF]

				K. Meisdalen, O. F. Dajani, T. Christoffersen, and D. Sandnes Prostaglandins Enhance Epidermal Growth Factor-Induced DNA Synthesis in Hepatocytes by Stimulation of E Prostanoid 3 and F Prostanoid Receptors J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1044 - 1050. [Abstract] [Full Text] [PDF]